Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 3/20 | 0.44 |
| ▸ | MME | P08473 | 3/20 | 0.44 |
| ▸ | ACE | P12821 | 1/20 | 0.44 |
| ▸ | CPA1 | P15085 | 1/20 | 0.44 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.37 |
| ▸ | ANPEP | P15144 | 1/20 | 0.37 |
| ▸ | ECE1 | P42892 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4811735 | 1.00 | SMN1; SMN2 (0.47) | SMN1; SMN2ALDH1A1MAPTFAAHMME | |
| SCHEMBL6309640 | 1.00 | SMN1; SMN2 (0.47) | SMN1; SMN2ALDH1A1MAPTFAAHMME | |
| SCHEMBL4809704 | 0.91 | MME (0.47) | SMN1; SMN2ALDH1A1MAPTFAAHMME | |
| SCHEMBL23376623 | 0.81 | ALDH1A1 (0.51) | SMN1; SMN2ALDH1A1MAPTFAAHMME | |
| SCHEMBL18674704 | 0.81 | ALDH1A1 (0.51) | SMN1; SMN2ALDH1A1MAPTFAAHMME | |
| SCHEMBL15435835 | 0.81 | ALDH1A1 (0.51) | SMN1; SMN2ALDH1A1MAPTFAAHMME | |
| SCHEMBL1476947 | 0.80 | SMN1; SMN2 (0.47) | SMN1; SMN2ALDH1A1MAPTFAAHMME | |
| SCHEMBL4811341 | 0.80 | SMN1; SMN2 (0.47) | SMN1; SMN2ALDH1A1MAPTFAAHMME | |
| SCHEMBL4189346 | 0.80 | ALDH1A1 (0.50) | SMN1; SMN2ALDH1A1MAPTFAAHMME | |
| SCHEMBL10076082 | 0.80 | ALDH1A1 (0.50) | SMN1; SMN2ALDH1A1MAPTFAAHMME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7470678-B2 | Diphenylazetidinone derivatives for treating disorders of the lipid metabolism | ASTRAZENECA AB (SE) | 2008-12-30 | — | — | US | disclosed |
| US-20050239766-A1 | Diphenylazetidinone derivatives for treating disorders of the lipid metabolism | ASTRAZENECA AB (SE) | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239766-A1 | Diphenylazetidinone derivatives for treating disorders of the lipid metabolism | CYP46A1, CYP27A1, CYP7A1 | SMN1; SMN2 4165/4885ALDH1A1 410/4885MAPT 1732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.